All Food and Drug Administration (FDA)-regulated products imported into the United States will now be reviewed and subject to FDA requirements, according to US Customs and Border Protection’s (CBP’s) inspection policy. Previously, “de minimis shipments,” or low-value shipments, of FDA-regulated products were exempt from this review. However, CBP reported that de minimis shipments were exploited for shipping pill presses, dangerous narcotics, and other illicit goods. The updated importation policy will likely have a significant impact on academic medical centers and start-up biotechnology and pharmaceutical companies that use imported biological samples for conducting research.